We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+14.09%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.87B
AUM Growth
+$407M
Cap. Flow
+$334M
Cap. Flow %
17.86%
Top 10 Hldgs %
60.38%
Holding
58
New
8
Increased
29
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$105M
2
STOK icon
Stoke Therapeutics
STOK
+$90.1M
3
MIST icon
Milestone Pharmaceuticals
MIST
+$72.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$32.3M
5
ILMN icon
Illumina
ILMN
+$26.6M

Top Sells

Rank Stock Value
1
LIVN icon
LivaNova
LIVN
+$42.3M
2
SIBN icon
SI-BONE Inc
SIBN
+$23.9M
3
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$20.4M
4
WVE icon
Wave Life Sciences
WVE
+$17M
5
ARWR icon
Arrowhead Research
ARWR
+$8.95M

Sector Composition

Rank Sector Weight
1 Healthcare 94.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMMB
51
Chemomab Therapeutics
CMMB
$11.9M
$233K 0.01%
811
-133
-14% -$46.3K
ECOR icon
52
electroCore
ECOR
$54.9M
– –
-34,569
Closed -$3.63M
LIVN icon
53
LivaNova
LIVN
$4.53B
– –
-435,136
Closed -$42.3M
IMDX
54
Insight Molecular Diagnostics
IMDX
$162M
– –
-64,444
Closed -$5.09M
SIBN icon
55
SI-BONE Inc
SIBN
$818M
– –
-1,269,194
Closed -$23.9M
WVE icon
56
Wave Life Sciences
WVE
$1.13B
– –
-436,777
Closed -$17M
CNCE
57
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-1,688,448
Closed -$20.4M
1 2
3

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q2 2019 Portfolio in Review

As of Q2 2019, RTW Investments held 58 positions worth $1.87B, up 28% from $1.47B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

RTW Investments deployed $334M of net new capital in Q2 2019, opening 8 new positions and adding to 29 existing holdings. Its largest new stake was Stoke Therapeutics: 3,355,466 shares worth $92.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Arrowhead Research, an estimated $8.95M trimmed.

  • RTW Investments's largest Q2 2019 buy was Stoke Therapeutics: 3,355,466 shares worth $92.6M.
  • RTW Investments added most to Alnylam Pharmaceuticals in Q2 2019, an estimated $105M increase.
  • RTW Investments's biggest Q2 2019 reduction was Arrowhead Research, cutting an estimated $8.95M.
  • RTW Investments fully exited LivaNova in Q2 2019, selling an estimated $42.3M.
  • RTW Investments's ten largest holdings make up 60% of its $1.87B portfolio in Q2 2019.
  • RTW Investments opened 8 new positions and closed 6 in Q2 2019.
  • RTW Investments's portfolio value rose 28% quarter-over-quarter to $1.87B.

Based on RTW Investments's 13F filing for Q2 2019, filed 14 Aug 2019.